Dr Vincent Launay-Vacher

All Stories

1. 
   Antibiotics and chronic kidney disease: Dose adjustment update for infectious disease clinical practice

   Article • Médecine et Maladies Infectieuses, June 2020, Elsevier

   Dr Vincent Launay-Vacher

2. 
   Clarification de la méthode utilisée pour adapter la posologie des médicaments chez les patients insuffisants rénaux : étude CLEAR

   Article • Néphrologie & Thérapeutique, February 2020, John Libbey Eurotext

   Dr Vincent Launay-Vacher

3. 
   Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy

   Article • Frontiers in Oncology, January 2020, Frontiers

   Dr Vincent Launay-Vacher

4. 
   Nausées-vomissements induits par les traitements anti-cancéreux (NVITAC) : quelle prise en charge en 2018 ? Mise à jour du référentiel AFSOS

   Article • Bulletin du Cancer, May 2019, Elsevier

   Dr Vincent Launay-Vacher

5. 
   Toxicité rénale des produits de contraste non iodés

   Article • Néphrologie & Thérapeutique, November 2018, Elsevier

   Dr Vincent Launay-Vacher

6. 
   A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia

   Article • Critical Reviews in Oncology/Hematology, September 2018, Elsevier

   Dr. Luiz H Arantes Jr., Dr Vincent Launay-Vacher

7. 
   Anticoagulants in frail patients. Seven situations at risk

   Article • JMV-Journal de Médecine Vasculaire, September 2018, Elsevier

   Dr Vincent Launay-Vacher

8. 
   Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology

   Article • The Lancet Oncology, June 2018, Elsevier

   Dr Vincent Launay-Vacher

9. 
   Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network

   Article • Journal of Onco-Nephrology, June 2018, SAGE Publications

   Dr Vincent Launay-Vacher

10. 
    OUP accepted manuscript

    Article • Nephrology Dialysis Transplantation, January 2018, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher, Prof. Maurizio Gallieni

11. 
    Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network

    Article • Clinical Kidney Journal, October 2017, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

12. 
    Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis

    Article • Expert Opinion on Drug Metabolism & Toxicology, February 2017, Taylor & Francis

    Dr Vincent Launay-Vacher

13. 
    Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

    Article • American Journal of Nephrology, January 2017, Karger Publishers

    Dr Vincent Launay-Vacher, Kenar Jhaveri

14. 
    Renal function and venous thromboembolic diseases

    Article • Journal des Maladies Vasculaires, December 2016, Elsevier

    Dr Vincent Launay-Vacher

15. 
    Course of chronic kidney disease in French patients

    Article • Clinical Kidney Journal, September 2016, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

16. 
    Renal insufficiency and cancer treatments

    Article • ESMO Open, August 2016, BMJ

    Dr Vincent Launay-Vacher

17. 
    Renal Dysfunction Has Statistically and Clinically Significant Deleterious Effects on Anticancer Drug Safety

    Article • Journal of Clinical Oncology, July 2016, American Society of Clinical Oncology (ASCO)

    Dr Vincent Launay-Vacher

18. 
    Effets rénovasculaires des antiangiogéniques

    Article • Bulletin du Cancer, July 2016, Elsevier

    Dr Vincent Launay-Vacher

19. 
    Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France

    Article • Supportive Care in Cancer, March 2016, Springer Science + Business Media

    Dr Vincent Launay-Vacher

20. 
    Drug–drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists

    Article • Annals of Oncology, January 2016, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

21. 
    Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network

    Article • Clinical Kidney Journal, January 2016, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

22. 
    P-176: Direct oral anticoagulant drugs and renal function

    Article • Annales de Cardiologie et d Angéiologie, December 2015, Elsevier

    Dr Vincent Launay-Vacher

23. 
    Onco-Nephrology: Core Curriculum 2015

    Article • American Journal of Kidney Diseases, November 2015, Elsevier

    Dr Vincent Launay-Vacher

24. 
    Tolérance rénovasculaire du bévacizumab dans le cancer du sein. Valeur pronostique de l’hypertension et de la protéinurie

    Article • Bulletin du Cancer, November 2015, Elsevier

    Dr Vincent Launay-Vacher

25. 
    Reply to the article Non-VKA oral anticoagulants: an update for the clinical biologists

    Article • Annales de biologie clinique, November 2015, John Libbey Eurotext

    Dr Vincent Launay-Vacher

26. 
    Anticancer Drugs in End-Stage Kidney Disease Patients

    Article • Seminars in Dialysis, April 2015, Wiley

    Dr Vincent Launay-Vacher

27. 
    Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)

    Article • Annals of Oncology, March 2015, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

28. 
    Adaptation posologique chez les patients insuffisants rénaux chroniques et évaluation de la fonction rénale : focus sur les patients de cardiologie

    Article • Annales de Cardiologie et d Angéiologie, February 2015, Elsevier

    Dr Vincent Launay-Vacher

29. 
    Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in postmenopausal women: a rationale for future clinical studies

    Article • Cancer Chemotherapy and Pharmacology, January 2015, Springer Science + Business Media

    Dr Vincent Launay-Vacher

30. 
    Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists

    Article • Targeted Oncology, September 2014, Springer Science + Business Media

    Dr Vincent Launay-Vacher

31. 
    New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment

    Article • Drugs, July 2014, Springer Science + Business Media

    Dr Vincent Launay-Vacher

32. 
    Renal insufficiency, mortality, and drug management in heart transplant. Results of the CARIN study

    Article • Transplant International, June 2014, Wiley

    Dr Vincent Launay-Vacher

33. 
    Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients

    Article • Cancer, April 2014, Wiley

    Dr Vincent Launay-Vacher

34. 
    Prevalence of renal abnormalities in chronic HBV infection: The HARPE study

    Article • Liver International, March 2014, Wiley

    Dr Vincent Launay-Vacher

35. 
    Incidence of Nephrogenic Systemic Fibrosis in Patients Undergoing Dialysis After Contrast-Enhanced Magnetic Resonance Imaging With Gadolinium-Based Contrast Agents

    Article • Investigative Radiology, February 2014, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

36. 
    Cancer and the kidney: individualizing dosage according to renal function

    Article • Annals of Oncology, October 2013, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

37. 
    An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs

    Article • Cancer Chemotherapy and Pharmacology, September 2013, Springer Science + Business Media

    Dr Vincent Launay-Vacher

38. 
    Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey

    Article • Supportive Care in Cancer, May 2013, Springer Science + Business Media

    Dr Vincent Launay-Vacher

39. 
    Malaria Prophylaxis in Patients with Renal Impairment

    Article • Drug Safety, February 2013, Springer Science + Business Media

    Dr Vincent Launay-Vacher

40. 
    Pulmonary Hypertension: Use of Oral Drugs in Patients with Renal Insufficiency

    Article • Clinical Drug Investigation, December 2012, Springer Science + Business Media

    Dr Vincent Launay-Vacher

41. 
    Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study

    Article • Annals of Oncology, October 2012, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

42. 
    Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads

    Article • Supportive Care in Cancer, September 2012, Springer Science + Business Media

    Dr Vincent Launay-Vacher

43. 
    Correspondance à propos de l’article « Rein et infection par le virus de l’immunodéficience humaine »

    Article • La Presse Médicale, September 2012, Elsevier

    Dr Vincent Launay-Vacher

44. 
    Importance of monitoring renal function in patients with cancer

    Article • Cancer Treatment Reviews, May 2012, Elsevier

    Dr Vincent Launay-Vacher

45. 
    Traitements de l’anémie par carence martiale en oncologie

    Article • Bulletin du Cancer, May 2012, Elsevier

    Dr Vincent Launay-Vacher

46. 
    Mise à jour des recommandations de la MASCC et de l’ESMO pour la prévention des nausées et vomissements chimio- et radio-induits: résultats de la conférence de consensus de Pérouse

    Article • ONCOLOGIE, April 2012, Springer Science + Business Media

    Dr Vincent Launay-Vacher

47. 
    European society of clinical pharmacy (ESCP) glossary of scientific terms: a tool for standardizing scientific jargon

    Article • International Journal of Clinical Pharmacy, March 2012, Springer Science + Business Media

    Dr Vincent Launay-Vacher

48. 
    Gestion des agents anticancéreux chez les insuffisants rénaux

    Article • Bulletin du Cancer, March 2012, Elsevier

    Dr Vincent Launay-Vacher

49. 
    Évaluation de la fonction rénale chez le patient atteint de cancer

    Article • Bulletin du Cancer, March 2012, Elsevier

    Dr Vincent Launay-Vacher

50. 
    Gestion des antalgiques chez les patients insuffisants rénaux en cancérologie

    Article • Bulletin du Cancer, March 2012, Elsevier

    Dr Vincent Launay-Vacher

51. 
    Gestion des chimiothérapies chez les patients hémodialysés

    Article • Bulletin du Cancer, March 2012, Elsevier

    Dr Vincent Launay-Vacher

52. 
    Gestion des thérapies ciblées chez les patients hémodialysés

    Article • Bulletin du Cancer, March 2012, Elsevier

    Dr Vincent Launay-Vacher

53. 
    Insuffisance rénale et cancer du sein

    Article • Bulletin du Cancer, March 2012, Elsevier

    Dr Vincent Launay-Vacher

54. 
    Tolérance rénale des thérapies ciblées

    Article • Bulletin du Cancer, March 2012, Elsevier

    Dr Vincent Launay-Vacher

55. 
    Risque de cancer chez les dialysés et transplantés rénaux

    Article • Bulletin du Cancer, March 2012, Elsevier

    Dr Vincent Launay-Vacher

56. 
    Traitements des métastases osseuses du cancer

    Article • Bulletin du Cancer, March 2012, Elsevier

    Dr Vincent Launay-Vacher

57. 
    Colony stimulating factors (CSF) biosimilars. Progress?

    Article • Targeted Oncology, January 2012, Springer Science + Business Media

    Dr Vincent Launay-Vacher

58. 
    Evaluation of current practice

    Article • Anti-Cancer Drugs, October 2011, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

59. 
    Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma

    Article • Urologic Oncology Seminars and Original Investigations, September 2011, Elsevier

    Dr Vincent Launay-Vacher

60. 
    Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease

    Article • Cancer Chemotherapy and Pharmacology, August 2011, Springer Science + Business Media

    Dr Vincent Launay-Vacher

61. 
    La formule aMDRD est la formule de choix pour évaluer la fonction rénale, y compris chez les patients de plus de 80ans : commentaire sur l’article de Andro et al.

    Article • La Revue de Médecine Interne, June 2011, Elsevier

    Dr Vincent Launay-Vacher

62. 
    MéMoPratic’ VDHA: guide de prescription pour les voies digestives hautes altérées

    Article • ONCOLOGIE, March 2011, Springer Science + Business Media

    Dr Vincent Launay-Vacher

63. 
    MéMoPratic’ VDHA*: douleurs et soins de support: guide de prescription pour les voies digestives hautes altérées

    Article • Douleur et Analgésie, March 2011, Springer Science + Business Media

    Dr Vincent Launay-Vacher

64. 
    Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study

    Article • Nephrology Dialysis Transplantation, February 2011, Oxford University Press (OUP)

    Prof Marc Froissart, Dr Vincent Launay-Vacher

65. 
    Cancer and renal insufficiency results of the BIRMA study

    Article • British Journal of Cancer, November 2010, Nature

    Dr Vincent Launay-Vacher

66. 
    Epidemiology of Chronic Kidney Disease in Cancer Patients: Lessons From the IRMA Study Group

    Article • Seminars in Nephrology, November 2010, Elsevier

    Dr Vincent Launay-Vacher

67. 
    Toxicité rénale des médicaments

    Article • Néphrologie & Thérapeutique, February 2010, Elsevier

    Dr Vincent Launay-Vacher

68. 
    Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: Results of the FINEST study

    Article • European Journal of Radiology, February 2010, Elsevier

    Dr Vincent Launay-Vacher

69. 
    Toxicités des chélates de gadolinium chez le patient insuffisant rénal

    Article • Sang thrombose vaisseaux, February 2010, John Libbey Eurotext

    Dr Vincent Launay-Vacher

70. 
    Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients

    Article • Annals of Oncology, January 2010, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

71. 
    Drug Management of Prostate Cancer: Prevalence and Consequences of Renal Insufficiency

    Article • Clinical Genitourinary Cancer, October 2009, Elsevier

    Dr Vincent Launay-Vacher

72. 
    Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): The TRY study

    Article • Liver Transplantation, September 2009, Wiley

    Dr Vincent Launay-Vacher

73. 
    Ostéonécrose mandibulaire et bisphosphonates : état actuel et perspectives

    Article • La Revue de Médecine Interne, August 2009, Elsevier

    Dr Vincent Launay-Vacher

74. 
    Renal insufficiency and anticancer drugs in elderly cancer patients: A subgroup analysis of the IRMA study

    Article • Critical Reviews in Oncology/Hematology, May 2009, Elsevier

    Dr Vincent Launay-Vacher

75. 
    Prise en charge des effets dermatologiques sous erlotinib. Résultats de l’étude PRECEDE

    Article • Cancer/Radiothérapie, April 2009, Elsevier

    Dr Vincent Launay-Vacher

76. 
    Renal Safety of Gadolinium-based Contrast Media in Patients with Chronic Renal Insufficiency

    Article • Radiology, March 2009, Radiological Society of North America (RSNA)

    Dr Vincent Launay-Vacher

77. 
    Hypertension and proteinuria: a class-effect of antiangiogenic therapies

    Article • Anti-Cancer Drugs, January 2009, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

78. 
    Lung Cancer and Renal Insufficiency: Prevalence and Anticancer Drug Issues

    Article • Lung, October 2008, Springer Science + Business Media

    Dr Vincent Launay-Vacher

79. 
    Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?

    Article • Annals of Oncology, October 2008, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

80. 
    Cetuximab Pharmacokinetics in End-Stage Kidney Disease Under Hemodialysis

    Article • Journal of Clinical Oncology, September 2008, American Society of Clinical Oncology (ASCO)

    Dr Vincent Launay-Vacher

81. 
    Prescrire les bisphosphonates IV pour la prise en charge des métastases osseuses chez le patient insuffisant rénal

    Article • Progrès en Urologie - FMC, September 2008, Elsevier

    Dr Vincent Launay-Vacher

82. 
    GPR-Antibactériens

    Article • Le Pharmacien Hospitalier, September 2008, Elsevier

    Dr Vincent Launay-Vacher

83. 
    Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

    Article • Breast Cancer Research and Treatment, August 2008, Springer Science + Business Media

    Dr Vincent Launay-Vacher

84. 
    Comment on: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study: reply

    Article • Rheumatology, April 2008, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

85. 
    Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer

    Article • Clinical Kidney Journal, April 2008, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

86. 
    Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

    Article • Cancer Chemotherapy and Pharmacology, March 2008, Springer Science + Business Media

    Dr Vincent Launay-Vacher

87. 
    Pharmacocinétique de l'amprénavir chez deux patients infectés par le VIH-1 et présentant une insuffisance rénale sévère et terminale

    Article • Médecine et Maladies Infectieuses, December 2007, Elsevier

    Dr Vincent Launay-Vacher

88. 
    Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study

    Article • Rheumatology, November 2007, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

89. 
    Letter

    Article • International Journal of Gynecological Cancer, November 2007, Wolters Kluwer Health

    Dr Vincent Launay-Vacher

90. 
    Vaccination and chronic kidney disease

    Article • Nephrology Dialysis Transplantation, October 2007, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

91. 
    Antiretroviral Drug Dosing Errors in HIV-Infected Patients Undergoing Hemodialysis

    Article • Clinical Infectious Diseases, September 2007, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

92. 
    1303 POSTER Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology (SIOG) clinical practice recommendations.

    Article • European Journal of Cancer Supplements, September 2007, Elsevier

    Dr Vincent Launay-Vacher

93. 
    1300 POSTER Chemotherapy in elderly patients with renal Insufficiency. Recommendations of the International Society of Geriatric Oncology (SIOG)

    Article • European Journal of Cancer Supplements, September 2007, Elsevier

    Dr Vincent Launay-Vacher

94. 
    Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations

    Article • Annals of Oncology, August 2007, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

95. 
    International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency

    Article • European Journal of Cancer, January 2007, Elsevier

    Dr Vincent Launay-Vacher

96. 
    Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

    Article • Cancer, January 2007, Wiley

    Dr Vincent Launay-Vacher

97. 
    Néphrotoxicité des médicaments: veille bibliographique janvier 2003–décembre 2005

    Article • Néphrologie & Thérapeutique, November 2006, Elsevier

    Dr Vincent Launay-Vacher

98. 
    Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure

    Article • Nephrology Dialysis Transplantation, September 2006, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

99. 
    Gemcitabine-induced thrombotic microangiopathy: a systematic review

    Article • Nephrology Dialysis Transplantation, September 2006, Oxford University Press (OUP)

    Dr Vincent Launay-Vacher

100. 
     Renal Tubular Drug Transporters

     Article • Nephron Physiology, June 2006, Karger Publishers

     Dr Vincent Launay-Vacher

101. 
     Renal insufficiency in cancer patients: Prevalence and implications on anticancer drugs management. Final results of the “IRMA” study

     Article • Bone, March 2006, Elsevier

     Dr Vincent Launay-Vacher

102. 
     Abnormal blood pressure circadian rhythm: A target organ damage?

     Article • International Journal of Cardiology, March 2006, Elsevier

     Dr Vincent Launay-Vacher

103. 
     Prescription des statines en cas d’insuffisance rénale

     Article • La Presse Médicale, February 2006, Elsevier

     Dr Vincent Launay-Vacher

104. 
     Drug-induced glomerulopathies

     Article • Expert Opinion on Drug Safety, December 2005, Informa Healthcare

     Dr Vincent Launay-Vacher

105. 
     Thrombocytopenia induced by nicotinamide in hemodialysis patients

     Article • Kidney International, December 2005, Elsevier

     Dr Vincent Launay-Vacher

106. 
     Néphrotoxicité des médicaments : veille bibliographique janvier 2003–décembre 2004

     Article • Néphrologie & Thérapeutique, November 2005, Elsevier

     Dr Vincent Launay-Vacher

107. 
     Hepatitis C infection and proteinuria

     Article • Kidney International, November 2005, Elsevier

     Dr Vincent Launay-Vacher

108. 
     Hepatitis C infection

     Article • Kidney International, November 2005, Elsevier

     Dr Vincent Launay-Vacher

109. 
     Drug-induced diabetes mellitus

     Article • Expert Opinion on Drug Safety, October 2005, Informa Healthcare

     Dr Vincent Launay-Vacher

110. 
     Immunosuppressive and calcimimetic drug-drug interactions

     Article • Kidney International, October 2005, Elsevier

     Dr Vincent Launay-Vacher

111. 
     Immunosuppressive and calcimimetic drug-drug interactions

     Article • Kidney International, October 2005, Elsevier

     Dr Vincent Launay-Vacher

112. 
     Viral Load and HIV-Associated Nephropathy

     Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2005, New England Journal of Medicine (NEJM/MMS)

     Dr Vincent Launay-Vacher

113. 
     FHD: An Index to Evaluate Drug Elimination by Hemodialysis

     Article • American Journal of Nephrology, August 2005, Karger Publishers

     Dr Vincent Launay-Vacher

114. 
     E.F.P. – European Fellowship for Pharmacists Promoting Clinical Pharmacy in Europe

     Article • Pharmacy World & Science, August 2005, Springer Science + Business Media

     Dr Vincent Launay-Vacher

115. 
     Thalidomide for the nephrologist

     Article • Nephrology Dialysis Transplantation, July 2005, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

116. 
     Antiretroviral drugs and the kidney: Further precisions

     Article • Kidney International, July 2005, Elsevier

     Dr Vincent Launay-Vacher

117. 
     Antiretroviral drugs and the kidney: Further precisions

     Article • Kidney International, July 2005, Elsevier

     Dr Vincent Launay-Vacher

118. 
     Néphropathie induite par les produits de contraste iodés, l’épuration extrarénale est-elle efficace en prevention ?

     Article • La Presse Médicale, June 2005, Elsevier

     Dr Vincent Launay-Vacher

119. 
     Statins' dosage in patients with renal failure and cyclosporine drug–drug interactions in transplant recipient patients

     Article • International Journal of Cardiology, May 2005, Elsevier

     Dr Vincent Launay-Vacher

120. 
     Toxicité rénale des anticancéreux

     Article • Néphrologie & Thérapeutique, May 2005, Elsevier

     Dr Vincent Launay-Vacher

121. 
     Antiviral Drug-Induced Nephrotoxicity

     Article • American Journal of Kidney Diseases, May 2005, Elsevier

     Dr Vincent Launay-Vacher

122. 
     Fanconi syndrome associated with didanosine therapy

     Article • AIDS, May 2005, Wolters Kluwer Health

     Dr Vincent Launay-Vacher

123. 
     Atazanavir: a novel inhibitor of HIV-protease in haemodialysis

     Article • Nephrology Dialysis Transplantation, March 2005, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

124. 
     Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study

     Article • Nephrology Dialysis Transplantation, March 2005, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

125. 
     Renal tubular transporters and antiviral drugs: an update

     Article • AIDS, March 2005, Wolters Kluwer Health

     Dr Vincent Launay-Vacher

126. 
     Treatment of pain in patients with renal insufficiency: The World Health Organization three-step ladder adapted

     Article • Journal of Pain, March 2005, Elsevier

     Dr Vincent Launay-Vacher

127. 
     Pharmacokinetic Considerations in the Treatment of Tuberculosis in Patients with Renal Failure

     Article • Clinical Pharmacokinetics, January 2005, Springer Science + Business Media

     Dr Vincent Launay-Vacher

128. 
     Antiretroviral Drugs and The Kidney: Dosage Adjustment and Renal Tolerance

     Article • Current Pharmaceutical Design, December 2004, Bentham Science Publishers

     Dr Vincent Launay-Vacher

129. 
     Why is a shrunken bladder and a nephrotic kidney an expression of the same disease?

     Article • Nephrology Dialysis Transplantation, December 2004, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

130. 
     Reply from the Authors

     Article • Kidney International, December 2004, Elsevier

     Dr Vincent Launay-Vacher

131. 
     Anemia and Diabetes

     Article • American Journal of Nephrology, December 2004, Karger Publishers

     Dr Vincent Launay-Vacher

132. 
     Using the right MDRD equation

     Article • Kidney International, November 2004, Elsevier

     Dr Vincent Launay-Vacher

133. 
     Doxycycline, gastrointestinal bleeding, and thrombotic microangiopathy

     Article • American Journal of Hematology, October 2004, Wiley

     Dr Vincent Launay-Vacher

134. 
     Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies

     Article • Kidney International, September 2004, Elsevier

     Dr Vincent Launay-Vacher

135. 
     Antiretroviral and immunosuppressive drug-drug interactions: An update

     Article • Kidney International, August 2004, Elsevier

     Dr Vincent Launay-Vacher

136. 
     Renal safety of tenofovir in HIV treatment-experienced patients

     Article • AIDS, April 2004, Wolters Kluwer Health

     Dr Vincent Launay-Vacher

137. 
     Nelfinavir and felodipine: a cytochrome P450 3A4?mediated drug interaction

     Article • Clinical Pharmacology & Therapeutics, April 2004, Nature

     Dr Vincent Launay-Vacher

138. 
     Lymphadenopathy and proteinuria

     Article • Nephrology Dialysis Transplantation, February 2004, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

139. 
     Epidemiology of microscopic polyarteritis: A 16-year study

     Article • Kidney International, February 2004, Elsevier

     Dr Vincent Launay-Vacher

140. 
     Ear and kidney syndromes: Molecular versus clinical approach

     Article • Kidney International, February 2004, Elsevier

     Dr Vincent Launay-Vacher

141. 
     Oculorenal manifestations in systemic autoimmune diseases

     Article • American Journal of Kidney Diseases, February 2004, Elsevier

     Dr Vincent Launay-Vacher

142. 
     Topiramate-induced renal tubular acidosis

     Article • The American Journal of Medicine, February 2004, Elsevier

     Dr Vincent Launay-Vacher

143. 
     Hemodialysis and ADAMTS-13

     Article • Blood Purification, January 2004, Karger Publishers

     Dr Vincent Launay-Vacher

144. 
     Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysis

     Article • Kidney International, December 2003, Elsevier

     Dr Vincent Launay-Vacher

145. 
     Dosing guidelines for fluconazole in patients with renal failure

     Article • Nephrology Dialysis Transplantation, November 2003, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

146. 
     Pharmacokinetics of tenofovir in haemodialysis

     Article • Nephrology Dialysis Transplantation, September 2003, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

147. 
     Medication misuse in hospitalized patients with renal impairment

     Article • International Journal for Quality in Health Care, August 2003, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

148. 
     Assessing residents' prescribing behavior in renal impairment

     Article • International Journal for Quality in Health Care, May 2003, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

149. 
     Drug-induced Fanconi's syndrome

     Article • American Journal of Kidney Diseases, February 2003, Elsevier

     Dr Vincent Launay-Vacher

150. 
     Eye and Kidney: From Clinical Findings to Genetic Explanations

     Article • Journal of the American Society of Nephrology, February 2003, American Society of Nephrology

     Dr Vincent Launay-Vacher

151. 
     Fanconi and Inappropriate Secretion of Antidiuretic Hormone Syndromes Secondary to Venlafaxine Therapy

     Article • October 2002, Karger Publishers

     Dr Vincent Launay-Vacher

152. 
     Pharmacokinetics of Tramadol in a Hemodialysis Patient

     Article • September 2002, Karger Publishers

     Dr Vincent Launay-Vacher

153. 
     Lymphopenia in Wegener’s Granulomatosis

     Article • September 2002, Karger Publishers

     Dr Vincent Launay-Vacher

154. 
     Retroperitoneal fibrosis due to Wegener’s granulomatosis: a misdiagnosis as tuberculosis

     Article • The American Journal of Medicine, August 2002, Elsevier

     Dr Vincent Launay-Vacher

155. 
     Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: Case report and review of the literature

     Article • Clinical Pharmacology & Therapeutics, June 2002, Nature

     Dr Vincent Launay-Vacher

156. 
     Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient

     Article • Nephrology Dialysis Transplantation, March 2002, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

157. 
     Article • Critical Care, January 2002, Springer Science + Business Media

     Dr Vincent Launay-Vacher

158. 
     Gabapentin neurotoxicity in a chronic haemodialysis patient

     Article • Nephrology Dialysis Transplantation, October 2001, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

159. 
     An appraisal of antiretroviral drugs in hemodialysis

     Article • Kidney International, September 2001, Elsevier

     Dr Vincent Launay-Vacher

160. 
     Pharmacokinetics of Abacavir in HIV-1-Infected Patients with Impaired Renal Function

     Article • August 2001, Karger Publishers

     Dr Vincent Launay-Vacher

161. 
     Effect of N-acetylcysteine on serum creatinine level

     Article • Nephrology Dialysis Transplantation, July 2001, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

162. 
     Neurotoxicity of Valacyclovir in Peritoneal Dialysis: A Pharmacokinetic Study

     Article • American Journal of Nephrology, May 2001, Karger Publishers

     Dr Vincent Launay-Vacher

163. 
     Severe methotrexate intoxication in a haemodialysis patient treated for rheumatoid arthritis

     Article • Nephrology Dialysis Transplantation, May 2001, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

164. 
     Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis

     Article • Nephrology Dialysis Transplantation, March 2001, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

165. 
     ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis

     Article • AIDS, March 2001, Wolters Kluwer Health

     Dr Vincent Launay-Vacher

166. 
     Pharmacokinetics of Ritonavir and Saquinavir in a Haemodialysis Patient

     Article • February 2001, Karger Publishers

     Dr Vincent Launay-Vacher

167. 
     Tolerance and Pharmacokinetics of High Doses of Interferon-alpha-2a in a Hemodialysis Patient

     Article • January 2001, Karger Publishers

     Dr Vincent Launay-Vacher

168. 
     Pharmacokinetic of nevirapine in haemodialysis

     Article • Nephrology Dialysis Transplantation, January 2001, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

169. 
     Dosage of Lamivudine in a Haemodialysis Patient

     Article • December 2000, Karger Publishers

     Dr Vincent Launay-Vacher

170. 
     Indinavir pharmacokinetics in haemodialysis

     Article • Nephrology Dialysis Transplantation, July 2000, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

171. 
     Baclofen unerotoxicity in a chronic haemodialysis patient

     Article • Nephrology Dialysis Transplantation, May 2000, Oxford University Press (OUP)

     Dr Vincent Launay-Vacher

172. 
     Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis

     Article • AIDS, March 2000, Wolters Kluwer Health

     Dr Vincent Launay-Vacher

173. 
     Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency

     Article • AIDS, October 1999, Wolters Kluwer Health

     Dr Vincent Launay-Vacher